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ABSTRACT
 
The effects of the kappa opioid agonist U-50,488 on morphine-

induced conditioned place preference (GPP), locomotor
 
activity and Fos immunoreactivity was assessed in 10-, 17­
and 35-day-old rats. It was predicted that kappa agonist
 
treatment would block the unconditioned and conditioned
 
behaviors produced by morphine (a mu opioid receptor
 
agonist). Conditioning and testing for the preweanling and
 
periadolescent (35-day-olds) rats were conducted in a three
 
compartment chamber consisting of two large end compartments
 
and a smaller middle chamber. Each end compartment had its
 
own distinct tactile and odor cues. Conditioning took place
 
over two days followed by a test day. In Experiment 1, 17­
day-old rats received saline only and were placed in a
 
compartment scented with 10 cc lemon or almond extract. On
 
the second conditioning day, rats were treated with morphine
 
(0.1, 0.2 and 0.5 mg/kg, i.p.) or saline, and then placed in
 
the opposite compartment scented with 10 cc lemon or almond
 
extract. The scents were counterbalanced across conditioning
 
days. In Experimental 2, the procedure was identical with
 
the exception that the 17-day-old rats were injected with U­
50,488 (2.0, 5.0 and 10 mg/kg, s.c.) or saline 30 min prior
 
to morphine (0.5 mg/kg, i.p.). In Experiment 3, 10-, 17-,
 
and 35-day-old rats received U-50,488 (2.0 mg/kg, s.c.) 30
 
min prior to morphine conditioning. The results of
 
111
 
Experiment 1 showed that morphine (0.5 mg/kg) produced a
 
place preference in 17-day-old rats without inducing
 
hyperactivity. In Experiment 2, U-50,488 blocked morphine-

induced CPP while increasing locomotor activity. Results
 
from Experiment 3 showed that morphine produced CPP in the
 
10- and 17-day-old rats, and that U-50,488 successfully
 
blocked this morphine-induced effect. Surprisingly, U-50,488
 
produced hyperactivity in the 10- and 17-day-ols, while
 
increasing rearing and wall climbing in the 10-day-old rats,
 
an effect partially blocked by morphine. Morphine or U­
50,488 did not affect either the place preference
 
conditioning or the locomotor activity of the 35-day-old
 
rats. Two hours after CPP testing, rats were sacrificed and
 
Eos immunoreactivity was assessed (Experiment 4). Young rats
 
showed Eos activity in the dorsomedial thalamus, posterior
 
hypothalamus, and the habenula: results not consistent with
 
adults. When taken together, these results indicate that
 
morphine.is rewarding in preweanling rats without inducing
 
locomotor activity. Eurthermore, these results demonstrate
 
that U-50,488 have opposite profiles of action in the
 
developing rat when compared to adult rats. Thus, it appears
 
that U-50,488 enhances DA functioning in the preweanling rat
 
while it depresses DA functioning in the adult rat. These
 
age-dependent differences in behavioral response may be used
 
for further understanding how the kappa opioid and DA system
 
interact.
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 INTRODUCTION,
 
Drug abuse and addiction are. serious sociomedical
 
problems in our society. One of the most abused classes of
 
drugs are the psychomotor stimulants, which includes both
 
cocaine and amphetamine (Wise & Bozarth, 1987). Users of
 
psychomotor stimulants report being swept by feelings of
 
well-being; they feel self-confident, energetic, alert,
 
friendly, outgoing, and they have less desire for food and
 
sleep (Gawin, 1991).
 
Another class of.abused drugs are the opiates. Opium, a
 
derivative from the seeds of the opium poppy, has been eaten
 
and smoked for centuries (Carlson, 1992, p. 131). Morphine,
 
one of the naturally occurring ingredients of opium, is used
 
as a pain killer and it possesses highly addictive properties
 
(Pinel., 1993, pp. 438-439). Heroin, also known as
 
diamorphine, is the most commonly abused opiate and,
 
curiously, its centrally active component is morphine (Di
 
Chiara & North, 1992). The effect most valued by opiate
 
addicts is the rush that follows intravenous injection
 
(Snyder, , 1980). Ths heroin rush has been described as a wave
 
of intense, abdominal, orgasmic pleasure that evolves into a
 
state of calmness, and drowsy euphoria (Snyder, 1980).
 
, Much of our understanding about drug abuse is based on
 
the observations that drugs possess the ability to act as
 
reinforcing stimuli (Wise, Bauco, Carlezon & Trojniar, 1992).
 
A great deal of research is currently being done to
 
understarid and determine the neural substrates that mediate
 
the reinforcing or rewarding actions of psychomotor
 
stimulants and opiate drugs. More specifically, current
 
research has focused on the anatomical, neurochemical and
 
developmental differences involved in reward mechanisms. In
 
general, research findings in these areas indicate that
 
dopamine (DA) is intimately associated with the rewarding
 
effects of psychomotor stimulants and opiates (McDougall,
 
Nonneman, & Crawford, 1991/ Phillips, 1984/ Wise, 1980/ Wise
 
& Rompr§, 1989).
 
Like many abused drugs, opiates activate dopamine
 
neurons, albeit indirectly, and affect behavior (see Di
 
Ghiara & North, 1992, for review). For example, systemic
 
injections of opiates increase feeding and lever-pressing for
 
brain stimulation (Broekkamp et al., 1976/ Mellb, Meldenson,
 
& Bree, 1981/ Morley & Levine, 1981). Also, animals, when
 
given a choice, will self-administer opiates intravenously,
 
and prefer the particular location where they previously
 
received the drug. Moreover, these opiate-induced behaviors
 
are blocked by dopamine antagonists such as haloperidol and
 
the opiate receptor antagonist naloxone (Bozarth, 1987a/
 
Bozarth & Wise, 1981/ Koob, 1992). The latter results
 
indicate again that the reinforcing properties of opiate
 
drugs are ultimately mediated through both opiate and
 
dopamine pathways. Curiously, the kappa agonist U50,488 also
 
blocks reward processes, presumably by depressing dopamine
 
functioning (Crawford, McDougall, Bolahos, Hall, & Berger, in
 
press).
 
The majority of studies assessing the pharmacology of
 
reward have been tested in mature organisms. However,
 
age-dependent differences in dopamine-mediated behaviors have
 
been reported (Bolanos, Duke, McDougall, & Crawford, 1994;
 
McDougall & Bolanos, 1995; McDougall, Crawford, & Nonneman,
 
1992a; Moody & Spear, 1992). Therefore, the purposes of this
 
study are: a) to pharmacologically assess the developmental
 
differences of morphine-induced reward as measured by the
 
conditioned place preference paradigm (CPP); b) to assess the
 
ability of the kappa opioid agonist U50,488, to block
 
morphine-induced reward; and c) to identify the brain areas
 
activated by thess drugs using Fos immunocytochemistry.
 
REWARD PATHWAYS.
 
The Law of Effect initially proposed by Edward Lee
 
Thorndike states that reward and punishment play a central
 
role in shaping behavior by increasing or decreasing the
 
probability for a particular behavior to occur in the future
 
(Domjan & Burkhard, 1993, p. 125). For example, an event
 
that increases the likelihood for a behavior to occur again
 
is called a reinforcer, whether this reinforcer is positive
 
or negative. A positive reinforcer is a stimulus that
 
increases behavior upon its presentation. Positive
 
reinforcers are normally associated with positive affect ,
 
(mood) and are usually referred to as rewards (Rovee & Rovee,
 
1969). A negative reinforcer is a stimulus that upon
 
"omission" produces an increase in behavior. An example of
 
negative,reinforcer is the omission of an electric shock when
 
a laboratory rat presses a lever. In this case, the rat will
 
repeatedly press a lever to stop the electric shock (Domjan &
 
Burkhard, 1993, p. 138).
 
Reward Svsterns: Neuroanatomica 1 Studies ,
 
The discovery of the positive reinforcing effects of
 
electrical self-stimulation of the brain led to the
 
conclusion that reward could occur as a consequence of brain
 
stimulation and that reward could also be studied
 
physiologically. (Olds & Milner, 1954)., In the search for the
 
neuronal substrates of reward, several paradigms have been
 
developed. Among others, neuroanatomical, pharmacological,
 
and neurochemical techniques have been widely used. The
 
neuroanatomical method is based on extensive mapping of the
 
brain. In 1954, Olds and Milner found that electrical
 
Stimulation of discrete brain regions (intracranial self-

stimulation; ICSS) could reinforce different types of
 
behavior in the rat. Since this discovery, many attempts
 
have been made to determine the different brain areas that
 
mediate reward, and to place them under a unified
 
neuroanatomical model of reward (Olds & Milner, 1954; Olds &
 
Olds, 1963).
 
The first neuroanatomical studies indicated that the
 
reinforcing effects of brain stimulation were mediated by,the
 
medial forebrain bundle (Olds & Olds, 1963; 1969). The
 
medial forebrain bundle is a large tract of mixed, long and
 
short, ascending fibers of various types: DA, NE
 
(norepinephrine), ACh (acetylcholine), and 5-HT (serotonin).
 
This bundle passes through the lateral hypothalamus, and its
 
ascending and descending axons interconnect forebrain and
 
midbrain areas. DA fibers from the VTA also travel through
 
the medial forebrain bundle and innervate discrete brain
 
areas, such as the nucleus accumbens, prefrontal cortex and
 
neostriatum. This DA pathway is known as the mesolimbic­
mesocortical pathway (Pinel, 1993, p. 448; Wise & Bozarth,
 
1984; Wise & Rompre, 1989).
 
In recent years, new findings have suggested that the
 
multiple brain sites mediating ICSS may not be interconnected
 
under a single anatomical brain reward substrate (Phillips,
 
1984). For example, animals show high rates of ICSS even
 
after damage to the entire medial forebrain bundle (Corbett,
 
Lafferi^re, & Milner, 1982). Also, substantial damage to the
 
mesolimbic DA system does not diminish "normal" self­
stimulation at the lateral hypothalamic level (Stellar,
 
Illes, Mills, 1982/ Wise & Rompre, 1989). Furthermore, PET
 
scan studies indicate that intracranial stimulation applied
 
to other brain areas that also mediate reward do not activate
 
the medial forebrain bundle. For example, electrical
 
stimulation to the medial prefrontal cortex and the locus
 
coeruleus do not activate the medial forebrain bundle,
 
indicating that stimulation to these brain areas is not
 
mediated by the same neuronal circuit (Gallistel, Gomita,
 
Yadin, & Campbell, 1985; Robertson, 1989; Yadin, Guarini, &
 
Gallistel, 1983).
 
Despite the different substrates that mediate ICSS,
 
electrical stimulation to the medial forebrain bundle
 
produces the highest rate of responding (Koob, 1992). Also,
 
the period of training necessary to obtain these high and
 
stable rates are much shorter for the medial forebrain bundle
 
than for other brain areas. Thus, these results indicate
 
again that the medial forebrain bundle may be the critical
 
anatomical pathway in mediating reward (Crow, 1972; German &
 
Bowden, 1974; Koob, 1992; Olds & Fobes, 1981; Robertson,
 
1989; Wise & Rompre,, 1989).
 
Pharmacological Studies: Rola nf da in Reward
 
Pharmacological studies have demonstrated that DA plays
 
an important role in mediating reward (Bozarth, 1987b; Le
 
Moal & Simon, 1991; Wise, 1978; Wise & Rompre, 1989).
 
Indirect dopamine agonists such as cocaine and amphetamine
 
are highly reinforcing and readily self-administered,(Wise,
 
1988). For example, cocaine and amphetamine increase bar
 
pressing for ICSS and drug self-administration into the
 
medial prefrontal cortex and nucleus accumbens (Goeders &
 
Smith, 1986; Hadfield & Nugent, 1983; Hoebel et al., 1983;
 
Pettit & Justice, 1991). Support for this notion comes from
 
studies showing that nonselective DA antagonists [i.e.,
 
pimozide and (+)-butaclamol] decrease the rate of intravenous
 
d-amphetamine self-administration (Yokel & .Wise, 1976).
 
Furthermore,,6-hydroxydopamine (6-OHDA) lesions of the
 
ascending DA fibers of the mesolimbic-mesocortical pathway
 
attenuate ICSS in the VTA (Fibiger, LePiane, Jakubovic, &
 
Phillips, 1987), and 6-OHDA lesions of the nucleus accumbens
 
produce a long lasting attenuation of cocaine self-

administration (Roberts, Koob, Klonoff, & Fibiger, 1980).
 
Numerous studies on DA receptor subtypes have implicated
 
DA Di and D2 receptors in reward (Nakajima, 1989). For
 
example, blockade of Di receptors with SCH 23390 reduces
 
operant responding for brain stimulation, food, and water in
 
adult rats'(Kurumiya & Nakajima, 1988; Nakajima, 1986;
 
Nakajima & McKenzie, 1986). Similarly, SCH 23390 attenuates
 
the rewarding effects of nipple attachment in rat pups
 
(McDougall et al., 1991; McDougall, Crawford, & Nonneman,
 
1992b). Other studies have reported that DA antagonists,
 
with a high affinity to the D2 receptor, attenuate ICSS and
 
operant responding for food (Gallistel & Davis, 1983/
 
Nakajima & Baker, 1989). Thus, both Di and D2 receptors
 
appear to be necessary for the full manifestation of reward
 
(Clark & White, 1987; Koechling, Colle, & Wise, 1988), In
 
agreement with this, combined treatment with Di and D2
 
antagonists produces maximal attenuation of reinforced
 
responding. For example, a SCH 23390-induced decline in
 
deprivation-induced feeding is potentiated by sulpiride (a D2
 
antagonist) in the adult rat (Koechling et al., 1988).
 
Similarly, sulpiride potentiates the reward depressing
 
effects of SCH 23390 in the preweanling rat fMcDougall et
 
al., 1991, 1992b).
 
Weurochemical Studies: Fluorescent Histochemistrv and Fog
 
Immunocvtochemistry
 
Brain mapping studies have demonstrated that DA fibers
 
are involved in brain stimulation, since many reward sites
 
are closely situated to dopaminergic pathways (Clavier &
 
Corcoran, 1976; Corbett & Wise, 1980). For example, Corbett
 
and Wise (1980) used movable stimulating electrodes, in
 
combination with fluorescence histochemistry, to map the
 
midbrain and the caudal diencephalon for ICSS. The electro-

histochemical data suggest that sites which supported ICSS
 
were restricted to areas where layers of DA cell bodies were
 
present.
 
Neuroanatomical (ICSS and lesion studies) and
 
pharmacological studies have been successful in identifying
 
the different nuclei involved in reward. However, electrode
 
implantation or lesions to discrete brain areas are likely to
 
activate or damage several components of the DA system (Le
 
Moal & Simon, 1991/ Wise & Rompre 1989). Thus, researchers
 
have recently started to neurochemically identify the
 
substrates involved in reward, the specific neurons within
 
these nuclei, and the neurochemicals within these neurons
 
(Watson, Trujillo, Herman, & Akil, 1989).
 
A number of studies have demonstrated that a series of
 
changes in a cell's gene transcription take place due to the
 
Cell's responses to stimuli such as stress or psychoactive
 
drugs (Dragunow & Robertson, 1990; Graybiel, Moratalla, &
 
Robertson, 1990). Therefore, an approach used to identify
 
these metabolically active neurons is Fos
 
immunocytochemistry. Fos, the product of the early response
 
gene c-fosh is transiently expressed in response to a variety
 
of physiological and pharmacological stimuli and can be used
 
as a marker for neuronal activation in the CNS (Miller, 1990;
 
Sagar, Sharp, & Curran, 1988). Neurotransmitter regulation
 
of gene expression is known to occur via a,second messenger-

dependent induction of a class of proteins, referred to as
 
transcription factors or proto-oncogenes (Montminy, Gonzalez,
 
& Yamamoto, 1990). Many of these proto-oncogenes have been
 
identified, including c-fos, c-jun, GREB, and several others.
 
Because of their position between cellular events (between
 
second messenger and gene ,transcription) they are also called
 
"third messengers'V (Sagar et al., 1988) ..
 
One of,the most widely studied of these factors is the
 
proto-oncogene c-fos. C-fos is activated by a variety of
 
different processes that influence cellular activity.
 
Recently, a number of studies have demonstrated that
 
activation of the mesostriatal and mesolimbic DA system
 
induces Fos-like immunoreactivity. For example, neuroleptics
 
such as haloperidol and clozapine increase c-fos expression
 
in rat forebrain structures (Robertson & Fibiger, 1992). It
 
has also been demonstrated that the amphetamine-stimulated
 
release of dopamine, as well as the direct activation of DA Di
 
receptors, produces c-fos induction in rat mesolimbic and
 
mesostriatal DA terminals (Dilts, Helton, & McGinty, 1993;
 
Robertson, Peterson, Murphy, & Robertson,:1989).
 
Furthermore, the ability of cocaine and amphetamine to induce
 
Fos is blocked by SCH 23390 (Graybiel et al., 1990; Young,
 
Porrino, & ladarola, 1991). More recently, our laboratory
 
demonstrated that the kappa agonist U-50,488 blocked cocaine-

induced "Fos activity in adult rats (Crawford et al., in
 
press). These results indicate that pharmacological
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manipulation can induce or block Fos activity/ and Fos, in
 
turn, can be used to identify the neurons and circuits
 
involved in the actions of drugs.
 
In summary, neuroanatomical, pharmacological and
 
immunocytochemical studies have contributed to the
 
identification of the neuronal circuits that mediate drug
 
reward. Psychopharmacological.studies, in particular, have
 
been important for determining the role of DA in mediating
 
the positive reinforcing properties of drugs (Bozarth,
 
1987b). Even though the existence of separate reward systems
 
has been suggested (see Phillips, 1984, for a review),
 
overwhelming evidence supports the existence of a general
 
reward DA pathway '(Watson et al., 1989; Wise & Bozarth,
 
1987). This reward pathway also known as the mesolimbic­
mesocortical pathway consists of: (1) descending fibers in
 
the medial forebrain bundle connecting the lateral
 
hypothalamus and the VTA, (2) opioid.peptide-containing
 
fibers that terminate in the ventral tegmental area, (3)
 
dopaminergic cells projecting from the VTA to the nucleus
 
accumbens, and (4) dopaminoceptive cells of nucleus accumbens
 
which carry the reward signal from these inputs to other
 
undetermined areas (Watson et al., 1989; Wise & BOzarth,
 
1984). Therefore, because of its implication for reward, one
 
of the purposes of this study is to determine those brain
 
areas activated by opiate-acting drugs. To that end, Fos
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 activity will be assessed across brain. It is predicted that
 
pronounced activity will be apparent in those brain areas
 
that make up the mesolimbic-mesocortical pathway.
 
OPIATE RECEPTORS AND REWARD
 
Qpiate -Receptorsi Location. Classificdtiony and Thein Profiles
 
of Action
 
: 0 opioid neurotransmitters have been
 
observed in brain areas (liitbic and forebrain structures)
 
that re mood states. Briefly,
 
ehkephalins, a type Of endog^hous opiate/ are natural
 
occurrihg peptidds which bind^^t opiate receptors (Hong,
 
Yang, Fratta, & Costa, 1977; La Motte, Snowman, Pert, &
 
Snyder, 1978). Opiate receptors have been classified into
 
three ittajbr subtypes: mu> delta/ and kappa (Lord/ Waterfield/
 
Hughes, & Kosterlitz, 1977). Ligand-receptor binding studies
 
: have reyedled that possesses high affihity fdr liiu: (}i)
 
receptors (Brady, Herkenham, Long, & Rothman, 1989). Delta
 
(5) receptors are activated by enkephalin, whereas kappa (K)
 
receptors are activated by deltrophins (Erspamer et al.,
 
1989; Wagner, Evans, & Chavkin, 1991).
 
Different profiles of action have been described for mu,
 
delta, and kappa receptors. Mu receptors are associated with
 
the positive reinforcing effects of opiates. For example, mu
 
agonists (e.g., morphine) lower the electric current'
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threshold for ICSS, indicating that morphine-like opiates
 
directly activate reward processes (for reviews see'Di Chiara
 
& North, 1992, and Koob, 1992). Additionally, morphine and
 
heroin are readily self-administered in the nucleus accumbens
 
and the VTA (Broekkamp, Phillips, & Cools, 1979; Jenck,
 
Gratton, & Wise, 1987; Olds, 1982). Delta receptors,
 
although less extensively studied, have also been implicated
 
in reward. For example, delta opiate agonists (e.g., DPDPE)
 
induce place preference conditioning, increase locomotor
 
activity, and induce feeding in satiated rats (Koob, 1992;
 
Shippenberg, Bals-Kubik, & Herz, 1987).
 
While mu and delta agonists function as positive
 
reinforcers, kappa receptor agonists induce aversive states.
 
For example, kappa agonists (ethylketazocine and tifluadom)
 
induce taste aversion, and U-50,488, a highly selective kappa
 
agonist induces both taste and place aversions (Bals-Kubik,
 
Herz, & Shippenberg, 1989; Bechara & van der Kooy, 1987;
 
Mucha & Herz, 1985). Recently, it has been demonstrated that
 
kappa agonists also modulate DA neurotransmission. For
 
example, U-50,488 blocks morphine-induced DA turnover in both
 
the mesolimbic and nigrostriatal DA system (Di Chiara &
 
Imperato, 1987; Narita, Suzuki, Funada, Misawa, & Nagase,
 
1993). In agreement with these findings, Di Chiara and
 
Imperato (1987) found that kappa agonists reduce DA release
 
in the nucleus accumbens and nigrostriatum of freely moving
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rats, while at the same time, reducing locomotor activity.
 
when taken together, these findings indicate that
 
opioid receptors modulate DA functioning: mu and delta
 
agonists stimulate, while kappa agonists inhibit DA activity
 
in brain areas associated with reward.
 
Role Of DA Neurons in Opiate hew^^^rd'
 
A close association between enkephalin containing fibers
 
and dopaminergic neurons has been established. For example,
 
concentrations.of enkephalin and large numbers of opiate
 
receptors are found in brain areas (e.g., the nucleus
 
accumbens and the VTA) containing DA neurons (Johnson, Sar, &
 
Stump, 1981; Mansour, Khachaturian, Lewis, Akil, & Watson,
 
1988; Waksman, Hamel, Delay-Goyet, & Rogues, 1986).
 
Intracranial injections of opiates into the VTA, an area
 
containing dopaminergic cell bodies labeled AlO, are
 
reinforcing (Watson et al., 1989). Consistsnt with these
 
f^iridings, electrophysiological evidence demonstrates that
 
application of morphine directly on AlO DA neurons causes a
 
pronounced membrane depolarization (Matthews & German, 1984).
 
In .addition, , both naloxone (an opiate receptor antagonist)
 
and pimozide (a dopamine receptor antagonist) block heroin's
 
rewarding effects, suggesting that opiate—mediated reward is
 
dependent on a dopaminergic substrate (Bozarth & Wise, 1981).
 
Thus, several lines of evidence suggest that the rewarding
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effects of opiates (i.e., morphine and heroin) are also
 
mediated by a central DA mechanism.
 
Like psychomotor stimulants (e.g., cocaine and
 
amphetamine), opiates have the ability to produce positive
 
reinforcing effects when injected into the nucleus accumbens,
 
VTA, lateral hypothalamus-and hippocampus (Bozarth, 1987b;
 
Broekkamp et al., 1979; Corrigal & Linseman, 1988; Olds,
 
1982; Watson et al., 1989). These areas are apparently
 
interconnected, as activation of opioid receptors in the VTA
 
causes the release of DA in the nucleus accumbens, medial
 
prefrohtal cortex, and lateral hypothalamus (Watson et al.,
 
1989; White, 1989). Consistent with this notion, it has been
 
demonstrated that intracranial injections of the Di receptor
 
antagonist SCH 23390 into the nucleus accumbens attenuates
 
the rewarding effects of ICSS in the VTA (Kurumiya &
 
Nakajima, 1988). Similarly, lesions of DA neurons in the
 
nucleus accumbens blocks cocaine, heroin, and morphine self-

administration, again showing that the nucleus accumbens play
 
a critical role in modulating opioid and DA reward (Dworkin,
 
Guerin, Goeders, & Smith 1988; Koob, Stinus, Le Moal, &
 
Bloom, 1989; Wise & Rompre 1989).
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Conditionet^ PXace Preference (CPP): DA-Opiate interaction
 
Although the different paradigms reviewed thus far
 
(e.g., ICSS, drug self-administration, etc.) have provided
 
important information on the neural substrates that mediate
 
reward, these procedures have some limitations.. For example,
 
in these paradigms, animals are-usually required to- perform
 
complex motor responses under the influence of neurochemicals
 
that may impair their sensorimotor processes (Ettenberg,
 
Koob, & Bloom, 1981), An approach that seems to avoid this
 
potential confound is the conditioned place preference (CPP)
 
paradigm. In this paradigm, a drug is paired with a specific
 
environment and saline is paired with an alternative
 
environment. After conditioning, animals are tested in a
 
drug-free state in which they have free access to both
 
environments simultaneously. Place preference conditioning
 
is apparent when the animal spends a significantly greater
 
percentage of time in the drug-paired environment.
 
Traditionally, odor, tactile and visual stimuli are used to
 
distinguish the environments of the CPP apparatus.
 
A number of different reinforcers have been used to
 
produce CPP. For example, CPP is produced by, injecting
 
amphetamine either systemically or directly into the ventral
 
tegmental area. Also, cocaine induces a robust CPP (Bardo,
 
Neisewander, & Miller, 1986; Carr & White, 1983/ Trujillo,
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Belluzzi, & Stein, 1991). The reinforcing effects induced by
 
cocaine and amphetamine are blocked by lesions to the
 
prefrental cortex, lesions of the nucleus accumbens and by
 
high doses of the D2 antagonist haloperidol (Isaac, Nonneman,
 
Neisewander, Landers, & Bardo, 1989; Spyraki, Fibiger, &
 
Phillips, 1983). However, others have reported that neither
 
6-OHDA lesions nor DA receptor blockers disrupt cocaine-

induced CPP (Morency & Beninger, 1986/ Spyraki, Fibiger, &
 
Phillips, 1982; Spyraki, Nomikos, & Varonos, 1987).
 
Interestingly, amphetamine- and cocaine-induced CPP is
 
blocked by opioid antagonists such as naloxone (Bilsky,
 
Montegut, Belong, & Reid, 1992; Trujillo et al., 1991). in
 
addition, the ICSS threshold-lowering effect of cocaine are
 
antagonized with naloxone (Bain & Kornetsky, 1986).
 
Furthermore, the mu receptor antagonists naltrexone and
 
buprenorphine reduce cocaine self-administration in non-human
 
primates and humans (Mello, Mendelson, Bree, & Lukas, 1989,
 
1990; Trujillo et al., 1991).
 
To further delineate the interaction between DA and
 
opiates in reward, it has been demonstrated that pretreatment.
 
with DA.antagonists attenuates the appetitive effects induced
 
by heroin and morphine (Bozarth, 1987a, 1987b; Bozarth &
 
Wise, 1981; Phillips & LePiane, 1980; Shippenberg & Herz,
 
1987; Watson et al., 1989). For example, haloperidol blocks
 
CPP produced by systemic injections of morphine and by
 
17
 
microinjectiohs of morphine into the VTA (Bilsky, Marglin, &
 
Reid, 1990; Phillips & LePiane, 1980; Schwartz & Marchok,
 
1974; van der Kooy, Mucha, 0'Shaughnessy, & Bucenieks, 1982)
 
Pretreatment with DA antagonists, as well as lesions to the
 
VTA, disrupts the rewarding effects of heroin self-

administration and heroin-induced CPP (Bozarth & Wise, 1981;
 
Spyraki et al., 1983). Furthermore, the DA antagonist SCH
 
23390 attenuates morphine-induced CPP (Leone & Di Chiara,
 
1987; Shippenberg & Herz, 1987). However, despite
 
overwhelming evidence implicating a central DA mechanism in .
 
mediating opiate-reinforcing properties, other researchers
 
have reported that neuroleptics, such as haloperidol and a­
flupentixol, do not attenuate the rewarding effects of
 
morphine-induced CPP nor heroin self-administration
 
(Ettenberg, Pettit, Bloom, & Koob, 1982; Mackey & van der
 
Kooy, 1985).
 
Although the interaction between the mu opioid and DA
 
systems is understood, the interactions between the kappa
 
opioid and DA system are less well delineated. However,
 
interactions do exist, as our laboratory has recently
 
demonstrated that the kappa agonist U-50,488 attenuates a
 
variety of cocaine-induced behaviors. For example, U-50,488
 
attenuates cocaine—induced locomotor activity and blocks
 
cocaine-induced reward (Crawford et al., in press).
 
Interestingly, these findings indicate that kappa neurons
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modulate those DA systems involved in both reward and
 
unlearned behavior. The mechanisms by which kappa agonists
 
depress behavior are unclear; however, the ability of kappa
 
agonists to reduce DA release in the nucleus accumbens and.
 
striatum may provide the basis for U-50,,488's dopamiiiergic
 
actions (Crawford et al.., in press; Di Chiara & Imperato,
 
1987; Werling, Fattali, Portoghese, Takemori, & Cox, 1988).
 
In summary, the data seem to leave little doubt'that
 
dopamine is important for mediating the rewarding properties
 
of both psychomotbr stimulants and opiate drugs (Bozarth &
 
Wise, 1981; Watson et al., 1989). Specifically, these data
 
indicate that: 1) DA neurons mediate opiate-induced reward,
 
2) DA antagonists are able to block these rewarding effects,
 
3) DA receptors in both the VTA and the nucleus accumbens are
 
important for the reinforcing actions of psychomotor
 
stimulants and opiate drugs, 4) kappa agonists (e.g., U­
50,488) attenuate DA mediated behaviors, perhaps by
 
decreasing- DA release into the nucleus accumbens, and 5)
 
direct DA antagonist treatment in the nucleus accumbens
 
attenuates the rewarding effects of psychomotor stimulants
 
and opiates microinjected or self-administered into the VTA.
 
These data also indicate that the CPP paradigm is'able to
 
assess the rewarding properties of psychoactive drugs, and,
 
unlike paradigms that involve operant responding, CPP
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dissociates motor performance from reward (Crawford et al.,
 
in press; Hoffman, 1989; Koob et al., 1989).
 
ONTOGENY OF REWARD
 
Behavioral and Developmental Differences in Response to Drugs
 
, " Analysis of brain function at the ontogenetic level has
 
produced important findings that have contributed to the
 
understanding of the organism as a whole. It has been
 
established that developing organisms often respond
 
differently to psychopharmacological challenge than adult
 
organisms (see Spear, 1979, for a review). For example, in
 
adult rats pretreatment with the irreversible DA antagonist
 
EEDQ attenuates the behavioral effects induced by NPA (a DA
 
agonist). In contrast, EEDQ does not attenuate the NPA-

induced behaviors in 11- and 17-day-old rat pups (McDougall &
 
Bolanos, 1995; McDougall et al., :1992a; Mestlin & McDougall,
 
1993). Rat pups also respond differently to psychomotor
 
stimulants when compared to adult rats. For example, when
 
given cocaine between 7 and 2T days of age, rat pups show
 
more locomotor responding than adult rats. At 28 days of
 
age, rats respond to cocaine in an adult typical manner
 
(Spear :& Brick, 1979).
 
Ontogenetic differences have also been observed in
 
animals treated with morphine. For example, Gaza and Spear
 
(1980) reported that at lO-day'^.old rats given low :(0.5, or
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1.0 mg/kg) or high (5.0 mg/kg) doses of morphine showed a 
decrease in locomotor activity. Interestingly, 17-day-old 
pups.given a low dose (0.5 mg/kg) of morphine showed an 
increase in locomotion, whereas a high dose (5.0 mg/kg) 
decreased loGomotor activity (Caza & Spear, 1980). These 
findings;are interesting, since adult■rats show an increase 
in locomotor activity at low doses (1.0 mg/kg) and-a decrease 
in locomotion at high doses (5.0 mg/kg) of morphine (Ayhan & 
Randrup, 1973/ Fog, 1970) . 
Ontoaenv of Reward and Receptor Development 
Although less extensively investigated, reward processes 
have been studied in young animals (Smith & Holman, 1987) . 
For example, electrical self-stimulation occurs in 3- and 10­
day-old rat pups in the same brain areas (i.e., nucleus 
accumbens, lateral hypothalamus, olfactory tubercle and 
medial forebrain bundle) as those found to be reinforcing in 
adult rats (Barr & Lithgow, 1986; Moran, Lew, & Blass, 1981, 
1983) . Similarly, systemic and intracerebroventricular 
injections of morphine induce CPP in rat pups (Barr & Rossi, 
1992; Kehoe & Blass, 1986b) . Thus, these findings indicate 
that the biological mechanisms that mediate reward are 
present in the neonate and appear to be similar to the neural 
substrates that mediate reward in the adult. 
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In the case of opiate receptors/ it has been
 
demonstrated that mu and kappa binding sites are present
 
before birth, and that delta binding sites emerge postnatally
 
(Spain, Roth, & Coscia, 1985). Consistent with this,
 
neurochemical studies have determined that mu and kappa
 
receptors appear to be functional in the rat at 17 days of
 
gestation, and delta receptors as early as 7 days postnatally
 
(DeVries, Hogenboom, Mulder, &•Schoffelmeer, 1990). These
 
findings are generally consistent with ontogenetic behavioral
 
data. For example, Jackson and Kitchen (1989) reported that
 
mu agonists (e.g., morphine and DAGO) produce behavioral
 
inhibition in 5-, 10- and 20-day-old rats, while kappa
 
agonists (e.g., U50,488 and PD117,302) produce hyperactivity
 
with increased wall-climbing at 5- and 10-days of age. In
 
contrast, the delta agonist DPDPE did not exert any
 
behavioral effects at any of the ages tested (Jackson &
 
Kitchen, 1989).
 
Periadolescence
 
A stage of development that has been relatively
 
understudied is periadolescence (approximately 28 to 40 days
 
of age). Periadolescerit animals are hyperactive and appear
 
to engage in more playful behavior than preweanling or adult
 
rats (see Spear & Brake, 1983, for review). Periadolescent
 
rats also show different behavioral responses when challenged
 
by■psychoactive drugs. For example, when given amphetamine, 
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18-dayT-old rats show adult-like behaviors, while 35-day-olds
 
failed to show the same adult-like responses (Infurna &
 
Spear, 1979). Also, periadolescents are less sensitive to
 
cocaine and apomorphine, tend to perform poorly on complex
 
learning tasks, but perform quite well on simpler learning
 
tasks (Shalaby & Spear, 1980; Spear & Brake, 1983; Spear ,&
 
Brick, 1979). Furthermore, low doses of morphine (1 and 2
 
mg/kg) increase locomotor activity in adult anim-als (Ayhan &
 
Randrup, 1973); however, the same doses of morphine
 
accentuate locomotor activity in periadolescents (Spear,
 
Horowitz, & Lipovsky, 1982). In agreement with this,
 
Laviola, Dell'Omo, Alleva and Bignami (1992) reported that
 
low doses of cocaine (e.g., 5 mg/kg) induced CPP in 21-day­
old rats, while the same dose failed to induce CPP in
 
periadolescents (31-day-olds).
 
In summary, analyses of-the development of brain
 
function have contributed to the understanding of the mature
 
organism. Brain substrates that mediate the rewarding
 
effects of electrical stimulation are functional in rats as
 
young as 3 days of age (Barr & Lithgow, 1986; Moran et al.,
 
1981). . Additionally, 7-day-old pups prefer the odor and the
 
environment where they received intraoral milk reinforcement
 
1990). Thus, the brain areas that mediate rewarding
 
and appetitive behavior appear to develop, at an early age.
 
Although-relatively understudied, research using
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periadolescents has provided interesting results.
 
Periadolescent rats appear hyperactive, they perform poorly
 
in complex learning tasks and respond differently than young
 
and adult animals when challenged- with cocaine, amphetamine
 
or morphine (Infurna & Spear, 1979; Shalaby & Spear, 1980;
 
Spear & Brick, 1979; Spear et al., 1982). Thus, another
 
purpose of the current study is to compare CPP in both
 
preweanling and periadolescent rats.
 
SUMMARY
 
The discovery of intracranial self-stimulation by Olds
 
and Milner- (1954) facilitated the localization of those brain
 
areas that mediate reward. Although, the possibility of
 
multiple reward systems cannot be discounted (see Phillips,
 
1984, for review), overwhelming evidence suggests that the DA
 
system is the primary neurosubstrate responsible for reward
 
(Wise & Rompre, 1989). Ontogenetic research has demonstrated
 
that brain areas which support reward in adult organisms also
 
mediate reward in the young animal (Laviola et al.,. 1992;
 
Moran et al., 1981; Spear, 1982), however some age dependent
 
differences in reward mechanisms have been reported. For
 
example, McDougall and colleagues (1991, 1992b) have
 
demonstrated that sulpiride, a D2 antagonist, potentiates the
 
reward depressing effects of the Di antagonist SCH 23390 in
 
11- and 17-day-old pups: an effect not consistent with adult
 
studies. Additionally,, periadolescent rats show behavior
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patterns which are inconsistent with both adult and
 
preweanling rats (Ayhan & Randrup, 1973/ Caza & Spear, 1980;
 
Fog, 1970; Laviola et al., 1992; Spear & Brake, 1983).
 
General Purpose and Hypotheses
 
Although the advantages of ontogenetic research have
 
been established, the majority of neurobehavioral studies
 
have been done using adult organisms (Spear, 1990). Thus,
 
this ontogenetic study took advantage of the immaturity of
 
the opioid system in the young rat to further assess the
 
neuropharmacology of reward. More specifically, this study
 
attempted to determine: a) the morphine-induced behaviors of
 
periadolescent and preweanling rats, b) whether the kappa
 
agonist U-50,488 can block the conditioned bahavior (CPP) of
 
various aged rats, and c) those neuroanatomical pathways
 
which exhibit Eos activity in response to place preference
 
conditioning. It was predicted that: 1) morphine would
 
induce CPP in 10- and 17-day-old rats but .fail to induce CPP
 
in the 35-day-old rat, 2) the kappa agonist U-50,488 would
 
block morphine-induced CPP, and 3) Eos activity would be
 
enhanced by morphine-induced CPP and blocked by U-50,488
 
pretreatment.
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EXPERIMENT 1
 
In studies using operand responding (e.g., self-

administration of drugs) to assess reward, animals are
 
required to perform motor re^sponses under the influence of
 
neurochemicals that may impair their sensorimotor processes
 
(Ettenberg et al., 1981). An approach that seems to avoid
 
these potential, confounds is the CPP,paradigm in which
 
animals'are tested in a drug-free state. (Hoffman, 1989).
 
When assessing drug—induced behaviors in young animals,
 
ongoing maturational changes can be a confounding variable.
 
Thus, an abbreviated CPP procedure is preferable (Laviola et
 
al., 1992/ Spear, 1990). Recently, Pruitt, Bolanos, and
 
McDougall (in press) have shown that a 3 day procedure is
 
sufficient'to establish a cocaine-induced CPP in preweanling
 
rats. Thus, in the present experiment, an abbreviated CPP
 
procedure (3 days) was used to assess morphine's ability to
 
induce CPP in 17-day-o.ld rats.
 
Method
 
Subjgets•. Subjects were 32 male and female rats of
 
Sprague-Dawley descent (Harlan), born and raised at
 
California State University, San Bernardino. Rats were
 
tested at 17 days of age. Litters were culled to a maximum
 
of ten or a minimum of eight pups at 3 days of age. Rat pups
 
were kept with the dam throughout behavioral testing.
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Assignment of subjects was random with no more than one rat
 
from each-litter placed into a particular testing group. The
 
colony room was maintained at 23-25° C and kept under a 12:12
 
light:dark cycle. Testing was conducted during the light
 
phase of the cycle. A protocol for the procedure was
 
approved by the Animal Care Committee.
 
The testing apparatus was a rectangular plywood chamber that
 
had three compartments separated by removable partitions.
 
The end compartments measured 15.5 x 15.5 x 21.5 cm high,
 
while the middle compartment measured 9 x 15.5 x 21.5 cm
 
high. All compartments were painted gray and were covered by
 
a clear Plexiglas top. One end compartment had smooth
 
plywood flooring; whereas the other end compartment had
 
plywood flooring scored (2 dm deep) in a checkerboard
 
fashion. Besides the tactile differences, both end
 
compartments were eguipped with an odor delivery system.
 
More specifically, beneath each end compartment, and
 
connected via 15 small holes in the floor, were rectangular
 
containers (4.5 cm deep) that were paftially filled with pine
 
wood chip bedding. Lemon and almond extract were applied to
 
the pinewood bedding of each container to provide distinctive
 
odor cues for the end compartments (10 cc of the extract were
 
used for conditioning and 1-cc was used for preference
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testing). Lemon and almond odors were purchased from
 
commerciai vendors (Irish, Inc).• During conditioning, solid
 
partitions were used to keep rats in the appropriate
 
compartments; whereas, during testing, the partitions were
 
raised- 5.5 cm, so that each rat could move freely between the
 
compartments.
 
Procedure and Drugs
 
In each, experiment there were two conditioning days
 
followed by a. test day. .On the conditioning days, two 30-min
 
conditioning sessions were presented 4 hr apart. On the
 
first day of conditioning, rats were given saline only and
 
were placed in a chamber scented with 10 cc of almond or
 
lemon extract. On the second conditioning day, rats received
 
morphine (0.1, 0.2, or 0.5 mg/kg) or saline (i.p.) and were
 
placed in the opposite chamber scented with 10 cc of almond
 
or lemon extract. The scents were counterbalanced across
 
conditioning days. Morphine sulfate (Research Biochemicals
 
Inc., Natick, MA, USA) was dissolved in distilled water and
 
was injected intraperitoneally (i.p.) at a volume of 5.0
 
ml/kg. On the. testing day, rats were given saline and had
 
free access to all chambers for 15 min.
 
Both conditioning and tes.t trials were videotaped for
 
scoring at a later date by experimenters blind to the
 
treatment conditions. During conditioning,. the data recorded
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included: locomotor activity (line-crossings), rearing, and
 
wall climbing. On the test day the data included: percent
 
and total time spent in the drug-paired chamber (CPP),
 
locomotor activity, rearing, and wall climbing. CPP was
 
defined as a rat. spending significantly more time in the
 
morphine-paired (lemon or almond) chamber. Locomotor.
 
activity (line-crosses), rearing, and wall climbing were
 
measured continuously, with line-crosses being defined as a
 
rat putting both forepaws and snout into an adjacent quadrant
 
in the CPP chamber.
 
Statistical Analyses . Analyses of variance (ANOVAs)
 
were used to assess CPP. Locomotor activity (line-crosses),
 
wall climbing, and rearing were analyzed using ANOVAs.
 
Significant main effects were further analyzed using Tukey
 
tests, (p. < .05). Analyses of wall climbing and rearing did
 
not reveal significant effects, so that data is not
 
presented.
 
riesults
 
Locomotor Activitv Purina Conditioning . Mean locomotor
 
activity counts of morphine-treated rat pups are shown in
 
Figure 1. On the conditioning day, the locomotor activity
 
(line-crosses) of pups receiving morphine (0.1, 0.2, or 0.5
 
mg/kg) did not differ from saline-treated rat pups.
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Conditioned Place.PrPiffirf^riQf^ . , The percent time and
 
total,time spent by 17-day--old rats, in the : drug-paired
 
compartment can-be seen in Figures ,2 and 3, Rats treated
 
with 0.5 mg/kg morphine spent.a significantly,greater
 
percentage of time in the drug-paired compartment than did
 
their saline controls, E (3,28) ,= 2.44, p < .05, and Tukey
 
tests (p < .05). Similarly, rats given 0.5 mg/kg morphine
 
spent more total time in the drug-paired compartment than
 
rats treated with saline, E (3,28) 3.12, p < .05, and Tukey
 
tests (p < .05). Rats given lower doses of morphine (0.1 or
 
0.2 mg/kg) did not differ from their saline-treated controls.
 
Conditioned Locomotor Activity . Mean locomotor
 
activity counts on the testing day are presented in Figure 4.
 
Previous morphine treatment did not affect.locomotor activity
 
on the test day. Thus, these results indicate that morphine
 
did not induce conditioned hyper or hypoactivity.
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FIGURE CAPTIONS
 
Mean number (+SEM) of line-crosses in the drug-

paired compartment of the GPP apparatus during both
 
conditioning sessions (30 min each). The 17-day-old rat pups
 
were injected with morphine (0.1, 0.2 and 0.5 mg/kg, i.p.) or
 
saline immediately prior to conditioning (n = 8).
 
Ei-gure 2. Mean percent time (+SEM) spent in the drug-paired,
 
chamber of the GPP apparatus on the test day (n = 8). Rats
 
were drug-free on the test day and allowed 900 sec access to
 
the three CQmpartments. The percent score was determined by
 
dividing the time spent in the drug-paired compartment by the
 
time spent in both the saline and drug-paired compartment
 
(drug-paired/saline-paired+drug-paired).
 
Figure—2.. Mean total time (+SEM) spent in the drug-paired
 
chamber of the GPP apparatus on the test day (n = 8). Rats
 
were drug-free on the test day and allowed 900 sec access to
 
the three compartments.. ..
 
Eigufe 4• Mean number (+SEM) of line-crosses in the GPP
 
apparatus on the test day, (ri = 8). Rats were drug-free on
 
the test day and allowed 900 sec access to the three
 
compartments.
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EXPERIMENT,2
 
In a pilot study; a number of moderate.and high.doses of
 
morphine (1.0, 2.0, 4.0, and 8.,0 mg/kg) were used to
 
determine whether this mu opioid agonist could induce CPP in
 
the preweanling rat. Results from,that study (data not
 
reported) indicated that none of these higher doses was
 
capable of inducing CPP. The results from Experiment 1
 
demonstrate that a low dose of morphine (0.5 mg/kg) is
 
rewarding and capable of inducing.CPP in the 17-day-old rat.
 
These results are consistent with a number of recent studies
 
showing.that lower doses of morphine are rewarding to
 
preweanling rats, while higher doses can be aversive (Kehoe &
 
Blass, 1985a, 1986b, 1989/ Randall, Kraemer, Dose, Carbary, &
 
Bardo, 1992).
 
While mu agonists (e.g. morphine) have been shown to
 
activate reward processes, kappa receptor agonists induce
 
a.versive states. However, the aversive effects induced by:
 
these drugs are dose-dependent, as several studies have : :,
 
demonstrated that a moderate dose of U-5.0,488 (4-5 mg/kg) is
 
without;significant aversive properties (Bals-Kubik et al.,
 
1989; Bechara & van der Kooy, 1987; Crawford et al., in
 
press; Mucha & Herz, 1985).
 
In the infant rat, U-50,488's effects are both dose and
 
age-dependent. Low doses of U-50,488 (e.g., 3.0 mg/kg) have
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been shown to produce CPP in 3—day-olds and place aversions
 
in the 7-day-old rat (Barr, 1993). Therefore, the purpose of
 
Experiment 2 was to determine.the dose at which U-50,488
 
would block morphine-induced .CPP, without inducing aversive
 
or appetitive states. ,
 
Method
 
Subjects. Subjects were 64 male and female rats tested
 
at 17 days of age.
 
Procedure and Drugs . The procedure was identical to
 
Experiment 1, with the exception that U-50,488 (2.0, 5.0, or
 
10.0 mg/kg, s.c.) or saline was given 30 min before
 
conditioning, while morphine (0.5 mg/kg, i.p.) or saline was
 
injected immediately prior to conditioning. Both morphine
 
and U-50,488 were obtained from Research Biochemicals Inc.
 
(USA) and were given at a volume of 5.0 ml/kg.
 
Statistical Analyses . CPP, locomotor activity, wall
 
climbing, and rearing were analyzed by 2 (agonist) X 4
 
(antagonist) ANOVAs. When appropriate, Tukey tests (p < .05)
 
were used for making post hoc comparisons. Analyses of wall
 
climbing and rearing did not reveal significant effects, so
 
that data is.not presented..
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Locomotor Activity Purina Conditioning , Mean locomotor
 
.aGtivity U-50,488 and morphine-treatdd;17-day-old
 
rats are shown in Figiire 5; Overall,,: rat pups receiving U- ,
 
5G,488 (2,0, 5.0 or lO,0 mg/kg) had sighificantly rriore
 
locomotor activity counts than saline-treated rats,
 
:pretreatment main eftectr E (3,56) =:13.40, p < .001. ?
 
U-50,488's activating effects were partially blocked by :
 
morphina, posttreatment main effect, £ (1/56) 12,64, p <
 
:'V001:i^'' ' ■ ■ r:" ■ 
Cohditioned Place Preference , The percent time and total
 
time spent in the drug-paired compartment by morphine-treated
 
17-day-old rats can be seen in Figures 6 and 7, Rat pups
 
treated with 0,5 mg/kg of morphine spent a significantly
 
greater percentage of time in the drug-paired compartment
 
than saline-treated pups, L (14) = 2,84, p < ,05, All doses
 
of U-50,488 (2,0, 5,0 and 10,0 mg/kg) appeared to block this
 
morphine-induced effect, as pups given morphine alone spent a
 
greater percentage of time in the drug-paired compartment
 
than pups given morphine and U-50,488, Pretreatment x
 
Posttreatment interaction, £ (3,56) =3,04, p < ,05, and
 
Tukey tests (p < ,05), Regardless of U-50,488 dose, rats : :
 
given U-50,488 and morphine did not differ from rats given
 
the kappa agonist alone,
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Once again, rats treated with only morphine spent
 
significantly more total time in the drug-paired chamber than
 
the saline controls, t. (14) = 2.43, p < .05. This preference
 
was apparently blocked by U-50,488, because rats treated with
 
both U-50,488 and morphine did not differ from the saline
 
controls. Overall, rats given 10 mg/kg (U-50,488) spent less
 
total time in the drug-paired compartment than rats injected
 
with a lesser dose of the kappa agonist (2.0 or 5.0 mg/kg),
 
pretreatment main effect, £ (3,56) = 3.22, p < .05, and Tukey
 
tests (p < .05). These results suggest that 10 mg/kg of U­
50,488 may be aversive. Neither the agonist main effect or
 
interaction were statistically significant.
 
Conditioned Locomotor Activity . Mean locomotor
 
activity counts on the test day are presented in Figure 8.
 
Treatment with U-50,488 or morphine did not affect locomotor
 
activity on the test day. Thus, there was no evidence of
 
U-50,488- or morphine-induced conditioned activity.
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FIGURE CAPTIONS
 
Figure 5. Mean number (+SEM) of line-crosses in the drug-

paired compartment of the GPP apparatus during both
 
conditioning sessions (30 min each). The I7-day-old pups
 
were injected with U-50,488 (2 mg/kg, s.c.) or saline 30 min
 
prior to drug conditioning, and morphine (0.5 mg/kg, i.p.) or
 
saline immediately prior to conditioning (n = 8),
 
Figure— Mean percent time (+SEM) spent in the drug-paired
 
compaitment of the GPP apparatus on the test day (n = 8).
 
Rats were drug-free on the test day and allowed 900 sec
 
access to the three compartments. The percent scored was
 
determine as in Figure 2.' .
 
Figure 1. Mean total time (+SEM) spent in the drug-paired
 
compartment of the GPP apparatus on the test day (n = 8).
 
Rats were drug-free on the test day and allowed 900 sec
 
access to the three compartments.
 
Figure—8.- Mean number (+SEM) of line-crosses in the GPP
 
apparatus on the test day (n = 8). Rats were drug-free on
 
the test day and allowed 900 sec access to the three
 
compartments.
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EXPERIMENT 3
 
Ontogenetic research has shown that preweanling rats
 
often respond differently to psychopharmacological challenge
 
than adults (see McDougall, Crawford, and Nonneman, 1995/ and
 
Spear, 1979, for reviews). Surprisingly, periadolescent rats
 
(approximately 28 to 40 days of age) exhibit drug-induced
 
responses which are different from both younger and older
 
animals (Spear & Brake, 1983). Therefore, the purpose of the
 
present experiment was to assess the effects of the kappa
 
agonist U-5G,488 on the morphine-induced behaviors of 10-,
 
17- and 35-day-old rats.
 
Method
 
Subjects . Subjects were 96 male and female rats of
 
Sprague-Dawley descent born and raised at California State
 
University, San Bernardino. Rats were tested at either 10,
 
17, of 35 days of age. The periadolescent rats were weaned
 
at 21 days of age and kept in separate cages, away from the
 
dam in groups of no more than 10 rats per cage.
 
Apparatus
 
The testing apparatus for the 10- and 17-day-olds was
 
the same as used in Experiments 1 and 2. For the 35-day­
olds, the testing apparatus was slightly bigger. The end
 
compartments measured 20 X 20 X 28 cm high, while the middle
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compartment measured 12 X 20 X 28 cm high. During testing,
 
the partitions were raised 9 cm, so that each rat could move
 
freely between compartments.
 
Procedure and Drugs . The same procedure was used as in
 
Experiment 2, with the exception that only a single dose of
 
U-50,488 (2.0 mg/kg) or saline was used. For the .10- and 17­
day-olds, morphine and U-50,488 were injected at a volume of
 
5.0 ml/kg, whereas 35-day-olds were injected at a volume of
 
2.0 ml/kg.
 
Statistical Analyses . CPP, locomotor activity, wall
 
climbing and rearing were analyzed by 2 (agonist) X 2
 
(antagonist) ANOVAs at each age. Significant main effects
 
were further analyzed using Tukey tests (p < .05).
 
Results
 
10-day-olds
 
Locomotor Activity During Conditioning . Mean locomotor
 
activity counts of U-50,488 and morphine-treated 10-day-old
 
rats are shown in Figure 9. Rat pups receiving U-50,488 (2.0
 
mg/kg) had significantly more locomotor activity counts than
 
saline-treated controls, pretreatment main effect, £ (1,36) =
 
91.85, p < .001. The increase in locomotor activity was
 
blocked by morphine, since rats pretreated with U-50,488 and
 
morphine had less activity counts than rats receiving the
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kappa agonist alone, Pretreatment x Posttreatment
 
interaction, £ (1,36) = 7.23, p <.01, and Tukey tests (p <
 
.05).
 
Rearing Purina r-onditi nni ng . Mean rearing counts of
 
the 10-day-old rats are presented in Figure 10. The kappa
 
agonist affected rearing, as 10-day-olds receiving U-50,488
 
(2.0 mg/kg) had significantly more rearing counts than
 
saline-treated rats,-pretreatment main effect, £ (1,36) =
 
31.56, p < .001. The U-50,488-induced increase in rearing
 
was partially blocked by morphine, since rats receiving U­
50,488 and morphine had fewer rearing counts than pups
 
treated with the kappa agonist alone, Pretreatment x
 
Posttreatment interaction, £ (1,36) = 4.65, p < .05, and
 
Tukey tests (p < .05).
 
Wall Climbing Purina Condition-ina . Mean wall climbing
 
counts are presented in Figure 11. Overall, rat pups
 
receiving U-50,488 (2.0 mg/kg) had significantly more wall
 
climbing counts than saline-treated rats, pretreatment main
 
effect, £ (1,36) = 31.56, p < .001.
 
Conditioned Place Preference . The percent time and
 
total time spent in the drug-paired compartment by morphine-

treated 10-day-old rats can be seen in Figures 12 and 13,
 
respectively. Percent time spent in the drug-paired
 
Cbmpartment was not. significantly affected by morphine or U­
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50,488. Rat pups treated with morphine alone spent
 
significantly more total time in the drug-paired chamber than
 
the saline controls, i. (18) = 2.48, p < .05. The morphine-

induced preference was blocked by U-50,488. More
 
specifically/ rats receiving both U-50,488 and morphine spent
 
significantly less time in the drug-paired compartment than
 
rats receiving morphine alone, Pretreatment x Posttreatment
 
interaction, E (3,31) - 4.43, p < .05, and Tukey test (p <
 
.05).
 
Conditioned Locomotor Activity . Mean activity counts
 
are shown in Figure 14. Rats receiving U-50,488 alone had
 
significantly fewer activity counts on the test day than rats
 
treated with saline, pretreatment main effect, E (1,36) =
 
13.9, p < .001. Thus, pretreatment with U-50,488 seemed to
 
induce a conditioned hypoactivity in 10-day-old rats.
 
17-day-Qld3
 
Locomotor Activitv Purina Cnnditionina . Mean locomotor
 
activity counts of the U-50,488 and morphine-treated 17-day­
old pups are presented in Figure 15. As in Experiment 2, U­
50,488 (2.0 mg/kg) treated rats had significantly more
 
locomotor activity counts than the saline-treated pups,
 
pretreatment main effect, E (1,28) = 26.71, p < .001.
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Rearing and Wall r-limbina Purina Conditioning .
 
Analyses of rearing and wall climbing did not reveal
 
significant effects/so the data is not presented.
 
Conditioned Placed Preference'. The percentage and
 
total total time spent in the drug-paired compartment by
 
morphine-treated 17-day-old rats are presented in Figures 12
 
and 13. Pups treated with 0.5 mg/kg morphine spent a
 
significantly greater percentage of time in the drug-paired
 
compartment than the control rats, t. (14) = 2.15, p < .05.
 
Similarly, pups treated with morphine alone spent
 
significantly more time in the drug-paired compartment than
 
the saline controls, p (14) = 2.38, p <.05. This morphine-

induce preference was blocked by U-50,488, since rats treated
 
with both U-50,488 and morphine spent significantly less time
 
in the drug-paired compartment than rats receiving morphine
 
alone, Pretreatment x Posttreatment interaction, £ (1,28) =
 
6.14, p < .05, and Tukey tests (p < .05).
 
Conditioned Locomotor Activity . Mean activity counts
 
on the test day are presented in Figure 16. U-50,488-treated
 
17-day-old rats had significantly fewer test day activity
 
counts than rats treated with saline, pretreatment main
 
effect, E (1,28) = 8.05, p < .01. Thus, like in the younger
 
pups, U-5Q,488 induced a conditioned hypoactivity.
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 35-day-Qlds
 
Locomotor Activity During Conditioning . Mean locoitiotor
 
activity counts of U-50,488 and morphine-treated 35-day-old
 
rats are shown in Figure 17. Neither morphine nor U-5Q,488
 
affected locomotor activity.
 
. Rearing and Wall Climbing Purina Conditioning .
 
Analyses of rearing and wall climbing did not reveal
 
sighificant effects, so the'data is not presented.
 
Conditioned Place Preference . The percent and total
 
time spent in the drug-paired compartment by morphine-treated
 
35-day-old rats are shown in Figures 12 and 13. Morphine
 
(0.5 mg/kg) did not induce a place preference in the
 
periadolescent rat.
 
Conditioned Locomotor Activity . Mean activity counts
 
of 35-day-old rats on the test day are presented in Figure
 
18. Treatment with U-50,488 or morphine did not affect
 
activity on the test day.
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FIGURE captions
 
Figure 9. Mean number (+SEM) of line crosses in the drug-

paired compartment of the CPP apparatus during both
 
conditioning sessions .(30 min each). The 10-day~old rats
 
were injected with U-50,488 (2 mg/kg, s.c.) or,saline 30 min
 
prior to conditioning, and:morphine . (0.5 m.g/kg i.p.)
 
immediately prior to conditioning (n = 8).
 
Figufg m. Mean number (+SEM) of rearing counts ..in the drug-

paired compartment of the CPP apparatus during both
 
conditioning sessions (30 min each). The 10-day-old rats
 
were treated as in Figure 9.
 
Figutd 11. Mean number (+SEM) of wall climbing counts in the
 
drug-paired compartment of the CPP apparatus during.both,
 
conditioning sessions (30 min each). The 10-day-old rats
 
were treated as, in Figure 9.
 
Figute—12.' Mean percent time (+SEM) spent in the drug-paired
 
compartment of the CPP apparatus on the test day (n = 8).
 
The 10-, 17- and 35-day-.old rats were drug-free on the test
 
day and allowed 900 sec. access to the three compartments.
 
The percent score was determine as in Figure 2.
 
Figure—13.. Mean total (+SEM) time^ spent in the drug—paired
 
compartment of the CPP apparatus on the test day (n = 8).
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The 10-, 17- and 35-day-old rats were drug-free on the test
 
day and allowed 900 sec access to the three compartments.
 
Figure 14. Mean number (+SEM) of line-crosses on the test
 
day (n = 8). The 10-day-old rats were drug-free on the test
 
day and allowed 900 sec access to the three compartments.
 
Figure 15. Mean number (+SEM) of line-crosses in the drug-

paired compartment of the CPP apparatus during both
 
conditioning sessions (30 min each). The 17-day-old rats
 
were treated as in Figure 9 (n = 8).
 
Figure 1^. Mean number (+SEM) of line-crosses on the test
 
day (n = 8). The 17-day-old rats were drug-free on the test
 
day and allowed 900 sec access to the three compartments.
 
Figure 17. Mean number (+SEM) of line-crosses in the drug-

paired compartment of the CPP apparatus during both
 
conditioning sessions (30 min each). The 35-day-old rats
 
were treated as in Figure 9.(n = 8).
 
Figure 10. Mean number, (+SEM) of line-crosses on the test
 
day,(n = 8). • The 17-day-old rats were drug-^free on the test
 
day and,allowed 900 sec access to the three compartments.
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EXPERIMENT 4
 
Numerous studies have shown that a series of changes in
 
gene transcription take place as: a cell responds to impinging
 
neural activity (Sheng & Grenberg, 1990). An approach used
 
to identify neuronal activation is Fos immunocytochemistry
 
(Sagar et al./ 1988). Recently, our laboratory demonstrated
 
that cocaine-induced CPP induces Fos in adult rats, and that
 
U-50,488 blocks this cocaine-induced neuronal activity
 
(Crawford et al., in press). Hence, the purpose of this
 
Study was to determine the neuroanatomical pathways which
 
exhibit Fos activity in response to place preference
 
conditioning in the, preweanling and periadolescent rat. It
 
was predicted that enhanced Fos activity would result from
 
morphine-induced place preference conditioning, an effect
 
that would be blocked by prior treatment with U-50,488.
 
Method
 
Subjects. Subjects were the 96 male and female rats
 
from Experiment 3.
 
Procedure and Drugs. Rats were anesthetized with
 
phenobarbital and rapidly perfused with 4% paraformaldehyde 2
 
hr after CPP testing. Following a postfixation period,'100
 
|im sections were cut from each brain using a Vibratome 1000
 
(Ted Pella, Inc., Redding, OA). Sections were washed three
 
times with 0.1 M phosphate buffer (PB) before being washed
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with an Endogenous Peroxidase Block (0.1 M PB containing
 
hydrogen peroxidase and methanol solution) for 10 min to
 
control for non-specific binding. All sections were then
 
washed three times with PB before being incubated with the
 
Fos primary antibody at a 1:5,000 dilution in HSS (0.1 M PB
 
containing 2% horse serum, 0.1% triton-XlOO, and 0.1% bovine
 
serum albumin). Sections were incubated in the primary
 
antibody for 48-72 hrs. Control sections from each rat were
 
run in the absence of the primary antibody. All sections
 
were then washed three times in PB and,incubated with a
 
biotmylated mouse anti rat secondary antxbody for 2 hr
 
(1:1000 dilution in HSS). Sections were washed three times
 
in PB and incubated for 2 hr in avidin—biotin—horseradish
 
peroxidase conjugate from ABC horse kits. Sections were then
 
washed three more times and incubated with 3,3'­
diaminobenzidine tetrahydrochloride and hydrogen peroxide.
 
After this procedure, sections were rinsed in PB and mounted
 
on chrom-alum slides. The slides were then air dried,
 
dehydrated, and coverslipped with permount. All washes
 
lasted 5 min each.
 
Coronal sections from the same brain region were then
 
selected from each rat quantitative analysis. The number of
 
distinguishable immunoreactive nuclei present within specific
 
regions of the brain were manually counted using a
 
magnification of 40x. At each selected region, one to three
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samples were be counted with the size of the sample area
 
being Imm^.
 
The primary antibody was a monoclonal antibody made to
 
the N-terminal end of the Fos molecule in mouse myeloma
 
cells. This primary antibody recognizes Fos and not Fos
 
related antigens. The secondary, antibody was a biotinylated
 
mouse-anti-rat secondary antibody purchased from Vector
 
Laboratories, Inc. (Burlingame, CA, USA). An avidib-biotin­
horseradish peroxidase conjugate from ABC horse kit was also
 
acquired from Vector Laboratories, Inc. This general
 
procedure was based on the method described by Crawford et
 
al. (in press).
 
A total of 4-6 rats from each group were randomly chosen
 
for analysis of Fos immunoreactivity. Similar coronal
 
sections from each rat were selected for quantitative
 
analysis. The number of distinguishable immunoreactive
 
nuclei present within the thalamus (1.5 A), habenula (1..3 A),
 
hypothalamus (1.8 A), and the nucleus accumbens (1.7 A) were
 
manually counted using a magnification of 40x. (The numbers
 
in parentheses represent sections anterior to bregma,
 
according to the rat brain atlas of Pellegrino & Cushman,
 
1967).
 
Statistical Analyses , Data from the
 
immunocytochemistry experiment were analyzed using a one—way
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ANOVA (for each brain region). When appropriate, Tukey tests
 
(p < .05) were used for making post hoc comparisons.
 
Results
 
10-day-olda
 
Effects of Conditioned Place Preference on Fns
 
Immunoreactivity . Mean number of Fos-positive nuclei in
 
various brain areas of rats are shown In Table 1. Overall,
 
10-day-old rats pretreated with U-50,488 showed a decrease in
 
the amount of Fos-positive nuclei in the dorsomedial thalamus
 
and posterior hypothalamus, pretreatment main effect,
 
£ (1,17) = 4.38, p <0.05, and pretfeatment main effect, ,
 
£ (1,17) = 7.59, p < 0.05, respectively. In addition,
 
morphine-treated rats showed a significant increase in the
 
amount of Fos-positive nuclei in the thalamus, posttreatment
 
main effect, £ (1,17) = 6.53, p < 0.05.
 
17-day-olds
 
Effects of Conditioned Place Preference on Fo.q
 
Immunoreactivity . The mean number of Fos-positive nuclei in
 
various brain areas of rats are shown in Table 2. Overall,
 
U-50,488 induced a significant decrease in the mean number of
 
Fos-positive nuclei in the habenula and posterior
 
hypothalamus of the 17-day-old rats, pretreatment main
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effect, E (1,13) = 5.25, ^ < 0.05, and pretreatment iria
 
effect, E (1/12) = 4.56, p < 0.05, respectively.
 
35-day-old3
 
Effects of Conditioned Place Prp.ff.i-(^nce nn Fns
 
Iirmunoreactivity . The mean number of Fos-positive nuclei in
 
various brain areas of rats bf 35-ciay-oid rats are shown in: \
 
Table 3. Overall,vperiadolescent ratS;pretreated with
 
U-50,488 showed an increase in FOS-positive nuclei in the
 
thaiaimus,:pretreatment iriain effect, E (1,15).. = 7.15;, p <
 
0.05. .-v 'v,.vV. . ■ 'it...;.' 
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 Table 1
 
Mean Number:of Fos-positive Nuclei in Various Brain Areas of
 
IQ-day-Old rats. Numbers RenrfiSfint Counts From IniTn 2 ^
 
lO-DAY-OLDS
 
00
 
0
 
SAL-SAL SAL-MORPH U50-SAL U50-MORPH
00
 
Dorsomedial Thalamus . 9.503'^ 16.50a 4.88^'
 10.66
 
Habehula 2.92 4.60 2.88 5.84
 
Posterior Hypothalamus 4.75a 5.90a 2.00
 2.50
 
Nucleus Accumbens 1.67 2.42 1.72
 
^Significantly different from U-SO,488-treated rats,
 
pretreatment main effect (p < .05).
 
^^Significantly different:^ from morphine-treated rats,
 
pOsttreatment main effect (p < •05).
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Table 2
 
Mean Nuinber of Fos-positive Nuclei in Various Brain Areas of
 
17-day-Old rats. Numbers Represent Connt.s From Imm 2 _
 
17-DAY-GLDS
 
SAL-SAL SAL-MORPH U50-SAL U50-MORPH
 
Dorsomedial Thalamus 9.88 6.25 5.25 7.10
 
Habenula 10.50a 4.25a 2.62
 1.60
 
Posterior Hypothalamus 7.25a 7.84a 3.50
 2.90
 
Nucleus Accumbens 3.11 2.78 0.83 2.20
 
^Significantly different from U-50,488-treated rats,
 
pretreatment main effect (p < .05).
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Table 3
 
Mean Number of Fos-positive Nuclei in Various Brain Areas of
 
35-d,ay-Qld rats. Numbers Represent Counts From 1mm ^ Area.
 
35-DAY-OLDS
 
SAL-SAL SAL-MORPH U50-SAL U50-MORPH
 
Dorsomedial Thalamus 5.883 7.903 12.00 11.10
 
Habenula 1.80 2,.00 2.10 5.,84
 
Posterior Hypothalamus 7.40 7,.00 7.80 8,.40
 
Nucleus Accumbens 1.75 5,.25 3.40 3.07
 
^Significantly different from U-50,488--treated rats.
 
pretreatment main effect (p < .05),
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DISCUSSION
 
The purpose of the present study was to examine the
 
effects of opioid agonists in the preweanling and
 
periadolescent rat to further assess the neuropharmacology of
 
reward. To that end, morphine-induced GPP was assessed in
 
10-,.17- and 35-day-old rats after treatment with the kappa
 
agonist U-50,488. In addition, the neuronal response to CPP
 
conditioning was examined by measuring the induction ofFos,
 
the protein product of the early response gene c-fos.
 
As expected, preweanling rats spent significantly more
 
time in the environment paired with 0.5 mg/kg morphine,
 
indicating that morphine was rewarding (see also Bozarth &
 
Wise, 1980; Funada, Suzuki, Narita, Misawa, & Nagase, 1993;
 
Kehoe & Blass, 1986b; Randall et al., 1992; Wise, 1989; Wise
 
& Bozarth, 1982). Pretreatment with U-50,488 attenuated the
 
preference for the morphine-paired environment, indicating
 
that kappa agonists are effective at blocking the conditioned
 
effects of morphine in the 10- and 17-day-old rat. This
 
effect appeared to be due to a diminution of morphine's
 
rewarding properties, since U-50,488 alone did not avert rats
 
from the drug-paired compartment. The latter point is
 
important, since kappa agonists have been reported to induce
 
place aversions in adult and preweanling rats (Barr, 1993;
 
Funada et al., 1993; Shippinberg & Herz, 1987). In the
 
preweanling rat, U-50,488's aversive effects appear to be
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 dose^dependent, as lower doses of U-50,488 (2-3 mg/kg) are
 
witHout significant aversive properties in 3--, 10-, and 17^
 
day-olds (Barr, 1993, Barr, Wang, & Garden, 1994; and the
 
present study). The issue of aversiveness becomes critical
 
for the interpretation Of these findings/ b a 0-50,488­
induced aversion could have been used to explain why rat pups
 
spent less time in the morphine-paired compartment.
 
Morphine did not induce GPP in the 35-day-old rats, as
 
morphine-treated rats responded similarly to their saline
 
controls. Morphine's inability to induce GPP in the 35-day­
old rats may be due to age-dependent differences in drug
 
responsiveness. For example, periadolescent rats are less
 
sensitive to morphine and amphetamine than younger or older
 
rats (Bauer & Duncan, 1975; Gaza & Spear, 1980; Spear &
 
Brake, 1983). In addition, doses of cocaine that are
 
reinforcing in preweanling and adults rats are less
 
reinforcing in the periadolescent animal (Laviola et al.,
 
1992; Spear, 1979, 1990). The mechanisms responsible for
 
this age-dependent effect are uncertain, but it may be due to
 
the maturation of DA autoreceptors in the mesolimbic pathway
 
(Shalaby & Spear, 1980; Spear & Brake, 1983).
 
; The pathways mediating reward processes have been at
 
least partially delineated. More specifically, feelings of
 
reward appear to be correlated with activity in the •
 
mesolimbic DA pathway, which projects from the ventral
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 tegmental area (VTA) to the nucleus accurrtbens (Di Chiara &
 
North/ 1992; Fallen, l988). Both the psychomotor stimulants
 
and. the mu opioids induce reward by activating this pathway,
 
but these drugs do it in quite different ways. For example,
 
cocaine ahd amphetamine act directly in the nucleus accumbdhs:
 
to increase synaptic DA; whereas, heroin and morphine :
 
indirectly activate the mesolimbic DA fibers by disinhibiting
 
GABA interneurons in the VTA (Di Chiara & Imperato, l987; Di
 
Chiara & North, 1992; Wise, 1988; Wise & Rompre, 1989).
 
Kappa opioid drugs presumably block reward by directly
 
inhibiting DA release in the nucleus accumbens (Spanagel,
 
Herz, & Shippenberg, 1992).
 
■ ■ ■ The pathways mediating the effects of rewarding drugs 
have also been mapped by using early genes as neuronal 
markers (Crawford et al., in press; Graybiel et al., 1990; 
Sagar et al., 1988) Thus, on the preference test day (i.e., 
when in a non-drug state), rats were tested for Fos 
immunoreactivity in order to determine those brain areas
 
activated during the expression of CPP. Unexpectedly, drug-

and saline-treated (control) rats showed Fos immunoreactivity
 
in the dorsomedial thalamus, posterior hypothalamus, and the
 
habenula. The pattern of neuronal activation exhibited by
 
these preweanling rats is not consistent with previous
 
findings in adults (Crawford et al., in press; Graybiel et
 
al., 1990; Young et al., 1991). For example, Crawford et al.
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(in press) have shown that the expression of cocaine-induced
 
CPP increases Fos immunoreactivity in the anterior cingulate
 
cortex, piriform cortex, lateral septal area, and olfactory
 
tubercles, without affecting baseline levels of Fos in the
 
control animals. In contrast, preweanling rats showed
 
moderate levels of Fos activity after both drug and saline
 
treatment (see Tables 1-3).
 
The reasons for the inconsistent Fos data are uncertain,
 
however three possibilities are apparent: first, it is
 
possible that morphine does not readily induce Fos; second,
 
young rats may exhibit high levels of non-specific Fos
 
activity; and third, the odor used on the test day may be
 
sufficient to substantially increase Fos. The first
 
possiblity seems unlikely since morphine has been shown to
 
increase Fos activity in adult, rats, albeit at much higher
 
doses (Liu, Nickolenko, & Sharp, 1994). The second
 
possibility, that immature animals have high baseline levels
 
of Fos, may have some validity, since growth factors are
 
known to induce C-fos activity (Alberts et al., 1989, pp.
 
756-757). Although speculative, it would not be surprising
 
if odor induced Fos activity, because Morgan and Curran
 
(1991) have found that a variety of non-specific stimuli
 
(e.g., electrical stimulation, heat stress, kainic acid
 
lesions, and nociceptive stimuli) are sufficient to induce
 
Fos. Consistent with this, the brain areas showing the
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greatest nuirnber of Fos-positive; (e.g., the habenula­
and the dorsomedial thalamus) are components of the olfactory
 
,system (Barf, 1979;'M 1989). So odor, ah important 
source of sensory information for the preweanling rat, may 
have induced high levels of Eos activity, which masked the 
conditioned effects of morphine. ■ ■ 
■ A very interesting aspect of this study involved 
drug-induced effects during conditioning. Surprisingly, 
acute treatment with the kappa agonist U-50,488 markedly 
increased the locomotor activity of 10- and 17-day-old rats, 
an effect partially blocked by morphine (see Figures 10 and 
11) Consistent with this, U-50,488 increased the rearing 
and wall climbing of 10-day-old rats. These results are in
 
contrast to studies using adult rats which typically:find
 
decreased activity after U-50,488 treatment (Crawford et al.,
 
in press; Di Chiara & Imperato, 1987; Spanagel et al., 1992),
 
On the other hand, U-50,488 did not affect the locomotor
 
activity of 35-day-old rats. The inability of U-50,488 to
 
increase the activity of 35-day-olds may indicate that
 
periadolescent rats are generally less sensitive to
 
pharmacological challenge than younger or older rats (Bauer &
 
Duncan, 1975; Infurna & Spear, 1979; Shalaby & Spear, 1980;
 
Spear & Brick, 1979; Spear, Shalaby, & Brick, 1980).
 
Alternatively, the lack of a U-50,488-induced increase in
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activity may simply reflect that 35-day-olds are responding
 
similar to adults.
 
In adults/ activatidn of the kappa opidid receptor is
 
generally associated with a decrease in locomotor activity
 
(Crawford et al in press; Di Chiara & Imperato, 1987;
 
Matsumoto,, Brinsfield, Patrick, & Walker, 1988). For
 
example, the kappa opioid receptor agonist U-50,488 blocks
 
cocaine-induced locomotor activity and induces behavioral
 
depression in mature rats and mice (Crawford et al., in
 
press; Crawford et al., 1994; Di Chiara & Imperato, 1987;
 
Jackson & Cooper, 1986; Leighton, Johnson, Meecham, Hill, &
 
Hughes, 1987). These actions are thought to be due to a
 
kappa-mediated reduction of DA release in the nucleus
 
accumbens (Crawford et al., 1994; Di Chiara & North, 1992;
 
Spanagel et al., 1992). If this explanation is accurate, it
 
makes the results of the present study even more surprising,
 
since U-50,488 increased the locomotor activity of the
 
preweanling rats. Locomotor activity, as well as rearing and
 
wall climbing, are known to be DA.mediated, so it is possible
 
that the kappa opioid system is somehow activating the DA
 
pathway in preweanling rats.• Thus, these data suggest that
 
U-50,488 enhances DA functioning in the preweanling rat,
 
while it depresses DA functioning in the adult rat.
 
In contrast to U-50,488's activating effects, morphine
 
(0.5 mg/kg), a mu opioid receptor agonist, did not affect the
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iocomotor activity of 10- and 17-day-old rats. This was not
 
surprising since low to moderate doses of morphine (0.5, 1.0,
 
and 5.0 mg/kg) often have sedative effects in preweanling
 
rats (Caza & Spear, 1980). Interestingly, morphine was able
 
to produce its rewarding effects without inducing
 
hyperactivity.1 finding is potentially of great ;
 
importance, since it has been postulated that the rewarding/
 
and psychomotor stimulant properties of addictive drugs are
 
mediated by the same biological mechanisms (see Wise &
 
Bozarth, 1987, for review). For example. Wise and Bozarth
 
(1987) contend that increased Iocomotor activity is an
 
integral part of a drug's rewarding properties. This appears
 
not to be the case in the preweanling rat, since morphine was
 
sbie to induce CPP without producing Iocomotor activity, and
 
U-50,488 was able to increase Iocomotor activity while
 
attenuating morphine's rewarding effects. Therefore, /it' ; ^
 
seems that in the preweanling rat reward processes and
 
Iocomotor activity can be dissociated in the preweanling rat.
 
This property may make the preweanling rat an excellent model
 
for studying reward processes.
 
As expected, morphine did not affect the Iocomotor
 
activity of the 35-day-old rats. This lack of effect may
 
have been due to age-dependent changes in a variety of
 
neurobiological systems, maturation of the blood brain
 
barrier (Caza & Spear, 1980), or an insufficient dose of
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morphine. The latter explanation seems unlikely however,
 
since periadolescent rats do not show an increase or decrease
 
in baseline activity when given 0.1, 0.5, l.Oy or lO mg/kg
 
ymprphine (Gaza & Spear, 1980).; v ­
: Pverall, ths fact that 35-day-61d rats showed a lack of 
responsiyeness to both U-50,488;and morphine is intriguing ; 
and: may indicate that those neurobiological systems Critical■ 
fdr reward are in a transitionai deveibpmental phase during 
the periadolescent;period.: The inability of U--50,488 er ^ 
morphine to induce behaviofal 'changes in the 3'5-day-pld may 
be due to the development pfautoreGeptors in the mesolimbic 
pathway, resulting in a temporary.decrease in the sensitivity 
of the DA projectidns; during the periadolescent peripd (Spiear 
& Brake, 1983) . Thus,, these findings may indicate that the 
"paradoxical" responses exhibited by periadolescents are due 
to a catecholaminergic hyposensitivity during this 
developmental period. 
Another unexpected result was that U-50,488 induced 
conditioned hypoactivity on the test day in both the I0- arid 
IV-day-old rats. The reasons for these results are unclear, 
however it is possible that acute treatment with U-50,488 had 
both locomotor activating properties and was somewhat 
aversive. Conditioned activity, which is often observed 
after treatment with reinforcing drugs, is thought to be due 
to the conditioned release of DA (Kiyatkin, 1993) Although 
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speculative, it is possible that conditioned hypoactivity,
 
which occurred after treatment with U~50,488, may be due to a
 
conditioned inhibition of DA release.
 
The present results are generally consistent with other
 
developmental psychopharmacological studies showing that as
 
the animal matures, new behaviors emerge as the underlying
 
neurobiological mechanisms become functional (see Spear,
 
1979; Zolman & McDougall, 1983, for additional reviews).
 
More specifically, previous studies have shown that the
 
behavior-activating properties of drugs are often
 
quantitatively greater in older animals (McDougall, Arnold &
 
Nonneman, 1990, McDougall, Duke, Bolanos, & Crawford, 1994;
 
Shalaby & Spear, 1980). Qualitative differences are also
 
occasionally apparent, as some drug-induced behaviors (e.g.,
 
grooming) emerge at various times during the preweanling
 
period, while other behaviors (e.g., wall climbing) only
 
occur during a restricted period (Moody & Spear, 1992;
 
Shalaby & Spear, 1980).
 
In the present study, examples of both quantitative and
 
qualitative ontogenetic differences were evident. For
 
example, morphine had quantitatively different effects on the
 
GPP performance of young and adult rats. More specifically,
 
doses greater than 0.5 mg/kg were unable to induce GPP in the
 
preweanling rat, whereas 2-5 mg/kg is often used to induce
 
GPP in the adult (Mackey & van der Kooy, 1984; Randall et
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al., 1992/..Reid, Marglin, Mattie, & Hubbell, 1988). More
 
importantly, a number of age-dependent qualitative behavioral
 
differences were also observed in the present study. An
 
excellent example is the lack of drug responsiveness
 
exhibited by periadolescent rats. However, the most dramatic
 
qualitative differences involved U-50,488 and activity, as
 
U-50,488 induced a dose-dependent increase in the locomotor
 
activity of preweanling rats. In contrast, similar doses of
 
U-50,488 decrease the locomotor activity of adults (Crawford
 
et al., in press; Di Chiara & Imperato, 1987; Jackson &
 
Cooper, 1986). These finding are of special importance,
 
because they indicate that the pattern of kappa/DA
 
interactions are profoundly different in the young and adult
 
rat. Presumably, this age-dependent difference can be used
 
as a tool for further understanding how the kappa opioid and
 
DA systems interact to mediate behavior.
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